372 related articles for article (PubMed ID: 30387367)
1. Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics.
Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
J Comp Eff Res; 2019 Jan; 8(1):45-54. PubMed ID: 30387367
[TBL] [Abstract][Full Text] [Related]
2. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Wu JJ; Pelletier C; Ung B; Tian M
J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
[TBL] [Abstract][Full Text] [Related]
3. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
4. Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
J Comp Eff Res; 2020 Aug; 9(11):767-779. PubMed ID: 32638609
[No Abstract] [Full Text] [Related]
5. Real-World Experience With Apremilast in the Treatment of Adults With Moderate to Severe Plaque Psoriasis in Québec: A Claims-Based Analysis of Drug Utilization and Healthcare Resource Utilization.
Poulin Y; Beauchemin C; Royer C; Gaudreau AJ; Yim C; Liu FF; Lachaine J
J Cutan Med Surg; 2020; 24(6):573-587. PubMed ID: 32597685
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis.
Wu JJ; Pelletier C; Ung B; Tian M
Curr Med Res Opin; 2020 Jan; 36(1):169-176. PubMed ID: 31517542
[No Abstract] [Full Text] [Related]
7. Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis.
Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
J Comp Eff Res; 2019 Jul; 8(9):699-709. PubMed ID: 31081676
[No Abstract] [Full Text] [Related]
8. Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status.
Feldman SR; Zhang J; Martinez DJ; Lopez-Gonzalez L; Marchlewicz EH; Shrady G; Mendelsohn AM; Zhao Y
J Dermatolog Treat; 2021 Mar; 32(2):203-211. PubMed ID: 31769703
[TBL] [Abstract][Full Text] [Related]
9. Real-world biologic and apremilast treatment patterns and healthcare costs in moderate-to-severe plaque psoriasis.
Feldman SR; Zhang J; Martinez DJ; Lopez-Gonzalez L; Marchlewicz EH; Shrady G; Mendelsohn AM; Zhao Y
Dermatol Online J; 2021 Jan; 27(1):. PubMed ID: 33560784
[TBL] [Abstract][Full Text] [Related]
10. Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis.
Kaplan DL; Ung BL; Pelletier C; Udeze C; Khilfeh I; Tian M
J Comp Eff Res; 2021 Aug; 10(12):989-998. PubMed ID: 34187202
[No Abstract] [Full Text] [Related]
11. Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue.
Takamura S; Sugai S; Taguchi R; Teraki Y
J Dermatol; 2020 Mar; 47(3):290-294. PubMed ID: 31867729
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis.
Armstrong AW; Betts KA; Sundaram M; Thomason D; Signorovitch JE
J Am Acad Dermatol; 2016 Oct; 75(4):740-746. PubMed ID: 27476973
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review.
Kahn JS; Casseres RG; Her MJ; Dumont N; Gottlieb AB; Rosmarin D
J Drugs Dermatol; 2019 Apr; 18(4):. PubMed ID: 31013012
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the Effect of Treatment Persistence on the Economic Burden of Moderate to Severe Psoriasis and/or Psoriatic Arthritis Patients in the U.S. Department of Defense Population.
Lee S; Xie L; Wang Y; Vaidya N; Baser O
J Manag Care Spec Pharm; 2018 Jul; 24(7):654-663. PubMed ID: 29952710
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysis.
Wu JJ; Wang CA; Jobson G; Davidson D; Kalirai S; Zhu J; Suryavanshi M; Mittal M; Patel V; Seigel L
J Dermatolog Treat; 2023 Dec; 34(1):2177095. PubMed ID: 36736349
[TBL] [Abstract][Full Text] [Related]
16. A cost-effectiveness and budget impact analysis of apremilast in patients with psoriasis in the Italian setting.
Barbieri M; Loconsole F; Migliore A; Capri S
J Med Econ; 2020 Apr; 23(4):362-370. PubMed ID: 31856619
[No Abstract] [Full Text] [Related]
17. Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis.
Kaplan DL; Ung BL; Pelletier C; Udeze C; Khilfeh I; Tian M
Clinicoecon Outcomes Res; 2020; 12():369-377. PubMed ID: 32765022
[TBL] [Abstract][Full Text] [Related]
18. Drug Survival of Biological Therapies for Psoriasis Treatment in Germany and Associated Costs: A Retrospective Claims Database Analysis.
Mahlich J; Alba A; Hadad LE; Leisten MK; Peitsch WK
Adv Ther; 2019 Jul; 36(7):1684-1699. PubMed ID: 31102203
[TBL] [Abstract][Full Text] [Related]
19. Real-world registry-based study on apremilast use in psoriasis and psoriatic arthritis in Finland.
Koskivirta I; Ruotsalainen J; Kurki S; Lakkakorpi P; Salminen-Mankonen H; Pirilä L; Harvima R; Palomäki A
Scand J Rheumatol; 2023 Sep; 52(5):549-555. PubMed ID: 36644971
[TBL] [Abstract][Full Text] [Related]
20. Psoriasis treatment patterns: a retrospective claims study.
Higa S; Devine B; Patel V; Baradaran S; Wang D; Bansal A
Curr Med Res Opin; 2019 Oct; 35(10):1727-1733. PubMed ID: 31081697
[No Abstract] [Full Text] [Related]
[Next] [New Search]